Claims for Patent: 9,161,920

Summary for Patent: 9,161,920

Title:	Pharmaceutical compositions for the coordinated delivery of NSAIDs
Abstract:	The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.
Inventor(s):	Plachetka; John R. (Chapel Hill, NC)
Assignee:	Pozen Inc. (Chapel Hill, NC)
Application Number:	14/515,627
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,161,920
Patent Claims:	1. A method of reducing the incidence of NSAID-associated gastric ulcers in a patient requiring chronic NSAID treatment and who is at risk of developing an NSAID-associated ulcer, wherein the method comprises administering to said patient in need thereof a pharmaceutical composition in unit dose form in the form of a tablet, said composition comprising: naproxen in an amount of 200-600 mg per unit dosage form; and esomeprazole in an amount of from 5 to 100 mg per unit dosage form, wherein upon introduction of said unit dosage form into a medium, at least a portion of said esomeprazole is released regardless of the pH of the medium, and release of at least a portion of said naproxen is inhibited unless the pH of said medium is 3.5 or higher. 2. The method of claim 1, wherein said naproxen is present in a core layer, wherein said core layer has a coating that inhibits its release from said unit dosage form unless said dosage form is in a medium with a pH of 3.5 or higher. 3. The method of claim 1, wherein said unit dosage form is a multilayer tablet comprising a core layer and one or more layers outside of said core layer. 4. The method of claim 3, wherein said core layer comprises naproxen. 5. The method of claim 3, wherein at least one of said one more layers outside said core layer comprises esomeprazole. 6. The method of claim 3, wherein said one or more layers outside of said core layer do not contain naproxen. 7. The method of claim 1, wherein the pharmaceutical composition further comprises at least one carrier. 8. The method of claim 1, wherein the pharmaceutical composition further comprises at least one auxiliary agent chosen from the group consisting of lubricants, preservatives, disintegrants, stabilizers, wetting agents, emulsifiers, salts, buffers, coloring agents, flavoring agents, and aromatic substances. 9. The method of claim 1, wherein the pharmaceutical composition further comprises at least one ingredient to adjust pH. 10. The method of claim 1, wherein said pain or inflammation is due to either osteoarthritis or rheumatoid arthritis. 11. A method of reducing the incidence of NSAID-associated gastric ulcers in a patient requiring chronic NSAID treatment and who is at risk of developing an NSAID-associated ulcer, wherein the method comprises administering to said patient in need thereof a pharmaceutical composition in unit dose form in the form of a tablet, said composition comprising: a core layer comprising naproxen, wherein said core layer has a coating that inhibits release of said naproxen from said core layer unless said dosage form is in a medium with a pH of 3.5 or higher; and a layer comprising esomeprazole, wherein said layer is has a non-enteric film coating that, upon ingestion by a patient, releases said esomeprazole into the stomach of said patient. 12. The method of claim 11, wherein naproxen is present in said unit dosage form in an amount of 200-600 mg. 13. The method of claim 11, wherein esomeprazole is present in said unit dosage form in an amount of from 5 to 100 mg. 14. The method of claim 11, wherein naproxen is present in said unit dosage form in an amount of between 200-600 mg and esomeprazole in an amount of from 5 to 100 mg per unit dosage form. 15. The method of claim 11, wherein said pain or inflammation is due to either osteoarthritis or rheumatoid arthritis.